Overexpression of GLI2 has been reported to cause resistance to targeted cancer therapy in cancer cells, and another study reported that knockdown of GLI1 and GLI2 restored sensitivity to vemurafenib-resistant cells (39, 40). The gene discussed is GLI1; the disease is cancer.